Skip to content

ApoE Genotyping Analysis in Patients With Suspected Non-haemorrhagic Amyloid Angiopathy

ApoE Genotyping Analysis in Patients With Suspected Non-haemorrhagic Amyloid Angiopathy

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06809062
Acronym
CAA-WMH-ApoE
Enrollment
100
Registered
2025-02-05
Start date
2025-02-01
Completion date
2025-12-31
Last updated
2026-06-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Amyloid Angiopathy

Keywords

Cerebral Amyloid Angiopathy

Brief summary

Ischaemic microangiopathic features have recently been incorporated into the criteria for cerebral amyloid angiopathy (CAA). ApoE genotyping (presence of the E4 allele) is routinely used to help determine the aetiology of a haemorrhagic microangiopathy found on MRI. Chronic ischaemic disease in CAA is characterised by the presence of : * multispot pattern on the FLAIR sequence * severe periventricular FLAIR hypersignals with posterior predominance The main aim of this study was therefore to analyse the frequency of the presence of one (or two) E4 allele(s) on ApoE genotyping in patients with suspected CAA based on ischaemic MRI involvement with a typical radiological pattern.

Interventions

None listed

Sponsors

Centre Hospitalier Universitaire de Nīmes
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients with ischaemic stroke (from causes other than CAA, as CAA is not a frequent cause of ischaemic stroke) with associated stigmata of microangiopathy on MRI that may suggest associated CAA. * Patients treated at Nîmes University Hospital

Exclusion criteria

* Patient refusing to participate

Design outcomes

Primary

MeasureTime frameDescription
ApoE genotypagebaselineTo analyse the frequency of the presence of one (or two) E4 allele(s) on ApoE genotyping in patients with suspected AAC. Endpoint: presence of the E4 allele (Yes/No).

Countries

France

Contacts

STUDY_DIRECTORAnissa MEGZARI

Centre Hospitalier Universitaire de Nīmes

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 19, 2026